Discontinued — last reported Q1 '23

Products & Services · Excess and obsolescence charges related to inventory

ADUHELM — Excess and obsolescence charges related to inventory

Biogen ADUHELM — Excess and obsolescence charges related to inventory remained flat by 0.0% to $275.00M in Q1 2023 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $275.00M to $275.00M. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ4 2021
Last reportedQ1 2023

How to read this metric

An increase suggests poor demand forecasting or product obsolescence, while a decrease indicates efficient inventory management.

Detailed definition

This metric represents the write-down of inventory value for a specific product due to expiration, lack of market demand...

Peer comparison

Common in pharmaceutical companies managing drug launches with uncertain market uptake.

Metric ID: biib_segment_aduhelm_excess_and_obsolescence_charges_related_to_inventory

Historical Data

6 periods
 Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Value$120.00M$275.00M$275.00M$275.00M$275.00M$275.00M
QoQ Change+129.2%+0.0%+0.0%+0.0%+0.0%
YoY Change+129.2%+0.0%
Range$120.00M$275.00M
CAGR+94.1%
Avg YoY Growth+64.6%
Median YoY Growth+64.6%
Current Streak5+ quarters growth

Frequently Asked Questions

What is Biogen's aduhelm — excess and obsolescence charges related to inventory?
Biogen (BIIB) reported aduhelm — excess and obsolescence charges related to inventory of $275.00M in Q1 2023.
How has Biogen's aduhelm — excess and obsolescence charges related to inventory changed year-over-year?
Biogen's aduhelm — excess and obsolescence charges related to inventory decreased by 0.0% year-over-year, from $275.00M to $275.00M.
What does aduhelm — excess and obsolescence charges related to inventory mean?
The cost of writing off inventory that can no longer be sold.